The Afirma Gene Expression Classifier (GEC) uses molecular diagnostics to analyze genetic information from fine-needle aspiration biopsies of thyroid nodules. This analysis helps differentiate benign nodules from suspicious ones, aiding in the diagnosis of thyroid cancer. A sample obtained through a biopsy is analyzed for the expression of specific genes associated with cancerous and benign thyroid cells. The results classify the nodule as either benign or suspicious.
This diagnostic approach assists physicians in making more informed decisions about patient management. It can reduce the number of unnecessary surgeries performed on benign nodules, sparing patients potential complications and costs. Prior to the development of such molecular tests, diagnostic uncertainty often led to a more aggressive approach, with more patients undergoing surgery to determine the nature of a thyroid nodule. The GEC provides valuable information to help guide clinical decision-making and personalize patient care.
